EUVIMEDEUVIMED entdecken
Kohortenstudie

Association of proprotein convertase subtilisin/kexin type-9 inhibitors with risk of nonmelanoma skin cancer: a retrospective cohort study

Cheng-Yuan Li iD, Wei-Ting Wang, Sheng-Hsiang Ma, Li-Wei Lo iD, Chen-Yi Wu, Wei-Chuan Chang, Yi-Ju Chen, Tai-Li Chen iD

British Journal of Dermatology · 2025

DOI: 10.1093/bjd/ljae438 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift British Journal of Dermatology, 2025. Verfasst von Cheng-Yuan Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Taipei Veterans General Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Skin Neoplasms, Basal Cell Carcinoma, PCSK9 Inhibitors, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Taipei Veterans General Hospital, Ministry of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Growing evidence has shown that cholesterol metabolism abnormalities involve carcinogenesis. Proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors have been reported to inhibit tumour progression and prevent ultraviolet-related skin damage.

Objectives

To investigate the association of PCSK9 inhibitors with the risk of nonmelanoma skin cancer (NMSC).

Methods

This retrospective cohort study analysed data from the US Collaborative Network in the TriNetX database. Adults aged ≥ 40 years with atherosclerotic cardiovascular disease (ASCVD) under statin therapy between 2016 and 2022 were identified. A target trial design was used to compare the risk of NMSC, including basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), in patients also treated with PCSK9 inhibitors or continuing statin treatment (the control group). Each head-to-head comparison involved propensity score matching. Hazard ratios (HRs) were estimated using Cox proportional hazard models. Stratified analyses based on age, sex, Fitzpatrick skin type and immune status were also performed.

Results

A total of 73 636 patients with ASCVD were analysed. Compared with the control group, patients with ASCVD initiating PCSK9 inhibitors had lower risks of developing NMSC [HR 0.78, 95% confidence interval (CI) 0.71–0.87], BCC (HR 0.78, 95% CI 0.69–0.89) and cSCC (HR 0.79, 95% CI 0.67–0.93). Subanalyses revealed a reduced risk of NMSC with each PCSK9 inhibitor, namely evolocumab and alirocumab. Stratified analyses showed similar results in patients aged 65–79 years, those older than 80 years and in men.

Conclusions

Our study indicated that patients with ASCVD taking PCSK9 inhibitors have a lower risk of incident NMSC than those not taking PCSK9 inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Skin NeoplasmsBasal Cell CarcinomaPCSK9 InhibitorsCarcinoma, Squamous CellAtherosclerosisHumansMaleRetrospective StudiesFemaleAgedMiddle AgedHydroxymethylglutaryl-CoA Reductase InhibitorsAdultAntibodies, Monoclonal, HumanizedRisk FactorsAged, 80 and overIncidenceProprotein Convertase 9

Substanzen

PCSK9 InhibitorsPCSK9 protein, humanHydroxymethylglutaryl-CoA Reductase InhibitorsAntibodies, Monoclonal, HumanizedevolocumabProprotein Convertase 9

Autor:innen und Institutionen

  • Department of Dermatology, Taipei Veterans General Hospital, Taipei, Taiwan.
  • School of Medicine, National Yang Ming Chao Tung University, Taipei, Taiwan.
  • Institute of Brain Science, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taiwan.
  • Department of Public Health, Institute of Public Health, National Yang Ming Chao Tung University, Taipei, Taiwan.
  • Cardiovascular Center, Department of Internal Medicine, Taipei Veterans General Hospital, Taiwan.

ORCID-Profile: Cheng-Yuan Li, Li-Wei Lo, Tai-Li Chen

Förderung

  • Taipei Veterans General Hospital
  • Ministry of Science and Technology

Zitieren

APA

Li, C. Y., Wang, W. T., Ma, S. H., Lo, L. W., Wu, C. Y., Chang, W. C., Chen, Y. J., & Chen, T. L. (2025). Association of proprotein convertase subtilisin/kexin type-9 inhibitors with risk of nonmelanoma skin cancer: a retrospective cohort study. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljae438

Vancouver

Li CY, Wang WT, Ma SH, Lo LW, Wu CY, Chang WC, et al. Association of proprotein convertase subtilisin/kexin type-9 inhibitors with risk of nonmelanoma skin cancer: a retrospective cohort study. British Journal of Dermatology. 2025. doi:10.1093/bjd/ljae438

BibTeX
@article{Li2025,
  author = {Li, Cheng-Yuan and Wang, Wei-Ting and Ma, Sheng-Hsiang and Lo, Li-Wei and Wu, Chen-Yi and Chang, Wei-Chuan and Chen, Yi-Ju and Chen, Tai-Li},
  title = {Association of proprotein convertase subtilisin/kexin type-9 inhibitors with risk of nonmelanoma skin cancer: a retrospective cohort study},
  journal = {British Journal of Dermatology},
  year = {2025},
  doi = {10.1093/bjd/ljae438}
}
Kostenlos starten →